Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Swedish Medical Center
With
AstraZeneca
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Advanced (stage III or IV), histologically or cytologically documented ovarian cancer or serious uterine cancer patients who relapsed after primary therapy with a platinum and a taxane. This includes:
* Platinum sensitive: relapsed at least 6 months following platinum treatment
* Platinum refractory: the cancer grew while on platinum treatment
* Platinum resistant: recurrence within 6 months of platinum treatment
Must have failed first line treatment
ECOG performance status 0-2
Must be able to swallow and retain oral medication
Life expectancy greater than 16 weeks
Must have normal organ and bone marrow function defined as follows:
* Hemoglobin ≥ 9.0 g/dL
* Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
* White blood cells (WBC) \> 3 x 10\^9/L
* Platelet count ≥ 100 10\^9/L
* Total bilirubin ≤ 1.5 x institutional upper limit of normal
* AST (SGOT)/ALT (SGPT) ≤ x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5 ULN
* Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN)
You may not be if
Any previous treatment with a PARP inhibitor, including olaparib
Any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment (or longer period depending on the defined characteristics of the agents used)
Currently receiving the following classes of inhibitors of CYP3A4: azole antifungals, macrolide antibiotics, and protease inhibitors
Second primary cancer except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years
Symptomatic uncontrolled brain metastases
Major surgery within 2 weeks of starting study treatment
Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)
Known active hepatic disease (i.e. Hepatitis B or C)
Uncontrolled seizures
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin or paclitaxel
Clareo Health | Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
